image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - HK
$ 6.13
0.822 %
$ 79.8 M
Market Cap
-19.16
P/E
1. INTRINSIC VALUE

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.[ Read More ]

The intrinsic value of one RGC stock under the base case scenario is HIDDEN Compared to the current market price of 6.13 USD, Regencell Bioscience Holdings Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RGC

image
FINANCIALS
0 REVENUE
0.00%
-4.74 M OPERATING INCOME
24.50%
-4.36 M NET INCOME
28.03%
-4 M OPERATING CASH FLOW
19.37%
5.24 M INVESTING CASH FLOW
8789.12%
102 K FINANCING CASH FLOW
-24.19%
0 REVENUE
0.00%
-2.42 M OPERATING INCOME
-209676.99%
-1.03 K NET INCOME
-0.00%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Regencell Bioscience Holdings Limited
image
Current Assets 8.11 M
Cash & Short-Term Investments 7.96 M
Receivables 153 K
Other Current Assets 0
Non-Current Assets 324 K
Long-Term Investments 0
PP&E 227 K
Other Non-Current Assets 97.7 K
Current Liabilities 194 K
Accounts Payable 0
Short-Term Debt 59.8 K
Other Current Liabilities 134 K
Non-Current Liabilities 25.9 K
Long-Term Debt 25.9 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Regencell Bioscience Holdings Limited
image
Revenue 0
Cost Of Revenue 746 K
Gross Profit -746 K
Operating Expenses 3.99 M
Operating Income -4.74 M
Other Expenses -374 K
Net Income -4.36 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-52.34% ROE
-52.34%
-50.98% ROA
-50.98%
-61.76% ROIC
-61.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Regencell Bioscience Holdings Limited
image
Net Income -4.36 M
Depreciation & Amortization 746 K
Capital Expenditures -5.38 K
Stock-Based Compensation 449 K
Change in Working Capital -585 K
Others -833 K
Free Cash Flow -4.01 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Regencell Bioscience Holdings Limited
image
RGC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.22 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Regencell Bioscience Holdings Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7 years ago
Aug 29, 2017
Bought 369 K USD
BELL THOMAS D JR
Director
+ 25000
14.76 USD
7 years ago
Aug 25, 2017
Bought 149 K USD
KAPLAN STEPHEN A
Director
+ 10000
14.87 USD
7 years ago
Aug 24, 2017
Bought 105 K USD
Ownby David
EVP, CFO and Treasurer
+ 7500
14.04 USD
7 years ago
Mar 09, 2017
Sell 455 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 20233
22.5 USD
7 years ago
Mar 09, 2017
Sell 577 K USD
DUNN GREGORY W
President and COO
- 26050
22.15 USD
7 years ago
Nov 23, 2016
Sell 272 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 11840146
22.95 USD
7 years ago
Nov 23, 2016
Sell 26.6 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 1159854
22.95 USD
8 years ago
Sep 07, 2016
Sell 669 K USD
DUNN GREGORY W
President and COO
- 30765
21.75 USD
8 years ago
Aug 08, 2016
Sell 148 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 6860584
21.6 USD
8 years ago
Aug 08, 2016
Sell 6.48 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 300000
21.6 USD
8 years ago
Aug 08, 2016
Sell 126 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 5839416
21.6 USD
8 years ago
Jun 29, 2016
Sell 1.05 M USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 49024
21.51 USD
8 years ago
Jun 15, 2016
Sell 507 K USD
DUNN GREGORY W
President and COO
- 25000
20.28 USD
8 years ago
Mar 14, 2016
Sell 1.59 M USD
MILES AMY E
CEO
- 75000
21.22 USD
8 years ago
Mar 15, 2016
Sell 587 K USD
MILES AMY E
CEO
- 28201
20.82 USD
9 years ago
May 19, 2015
Sell 407 K USD
DUNN GREGORY W
President and COO
- 19000
21.4 USD
9 years ago
Mar 13, 2015
Bought 1.99 K USD
Weigand Nestor R Jr
Director
+ 88.144
22.54 USD
9 years ago
Feb 18, 2015
Sell 670 K USD
YEMENIDJIAN ALEX
Director
- 28638
23.38 USD
9 years ago
Feb 18, 2015
Sell 697 K USD
YEMENIDJIAN ALEX
Director
- 29837
23.36 USD
10 years ago
Jun 05, 2014
Sell 502 K USD
DUNN GREGORY W
President and COO
- 25000
20.09 USD
13 years ago
Feb 28, 2011
Sell 1.35 M USD
DUNN GREGORY W
President and COO
- 90000
15 USD
14 years ago
Jul 12, 2010
Sell 100 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 7299270
13.7 USD
14 years ago
Jul 12, 2010
Bought 80 M USD
ANSCHUTZ PHILIP F
10 percent owner
+ 5839416
13.7 USD
14 years ago
Jul 12, 2010
Bought 20 M USD
ANSCHUTZ PHILIP F
10 percent owner
+ 1459854
13.7 USD
14 years ago
Nov 23, 2009
Bought 27.3 K USD
Weigand Nestor R Jr
Director
+ 2000
13.64 USD
15 years ago
Nov 11, 2009
Sell 101 M USD
ANSCHUTZ PHILIP F
10 percent owner
- 7500000
13.41 USD
15 years ago
Nov 11, 2009
Bought 101 M USD
ANSCHUTZ PHILIP F
10 percent owner
+ 7500000
13.41 USD
15 years ago
Jun 05, 2009
Bought 37.8 K USD
Weigand Nestor R Jr
Director
+ 3000
12.59 USD
15 years ago
Nov 25, 2008
Bought 72.8 K USD
THOMAS LEE M
Director
+ 8960
8.1202 USD
15 years ago
Nov 25, 2008
Bought 8.48 K USD
THOMAS LEE M
Director
+ 1040
8.15 USD
15 years ago
Nov 25, 2008
Bought 30.7 K USD
BELL THOMAS D JR
Director
+ 3600
8.5383 USD
15 years ago
Nov 24, 2008
Bought 97.7 K USD
BELL THOMAS D JR
Director
+ 11400
8.5698 USD
16 years ago
Nov 21, 2008
Bought 71.6 K USD
Ownby David
SVP and Chief Act. Officer
+ 10000
7.16 USD
16 years ago
Nov 19, 2008
Bought 225 K USD
KAPLAN STEPHEN A
Director
+ 25000
9 USD
16 years ago
Nov 12, 2008
Bought 19.3 K USD
Weigand Nestor R Jr
Director
+ 2000
9.65 USD
16 years ago
Nov 07, 2008
Bought 933 USD
TYRRELL JACK
Director
+ 95
9.82 USD
16 years ago
Nov 07, 2008
Bought 244 K USD
TYRRELL JACK
Director
+ 24905
9.79 USD
16 years ago
Nov 07, 2008
Bought 15.6 K USD
TYRRELL JACK
Director
+ 1600
9.76 USD
16 years ago
Nov 07, 2008
Bought 228 K USD
TYRRELL JACK
Director
+ 23400
9.73 USD
16 years ago
Nov 07, 2008
Bought 238 K USD
KAPLAN STEPHEN A
Director
+ 25000
9.5 USD
16 years ago
Nov 06, 2008
Bought 101 K USD
KAPLAN STEPHEN A
Director
+ 10000
10.1 USD
16 years ago
Nov 06, 2008
Bought 154 K USD
KAPLAN STEPHEN A
Director
+ 15000
10.25 USD
16 years ago
Nov 06, 2008
Bought 18.4 K USD
TYRRELL JACK
Director
+ 1800
10.2 USD
16 years ago
Nov 06, 2008
Bought 29.5 K USD
TYRRELL JACK
Director
+ 2900
10.18 USD
16 years ago
Nov 06, 2008
Bought 208 K USD
TYRRELL JACK
Director
+ 20300
10.24 USD
16 years ago
Nov 06, 2008
Bought 32.9 K USD
TYRRELL JACK
Director
+ 3064
10.75 USD
16 years ago
Nov 06, 2008
Bought 74.4 K USD
TYRRELL JACK
Director
+ 6936
10.72 USD
16 years ago
Nov 06, 2008
Bought 430 K USD
TYRRELL JACK
Director
+ 40000
10.74 USD
16 years ago
Nov 06, 2008
Bought 79.1 K USD
TYRRELL JACK
Director
+ 7800
10.14 USD
16 years ago
Nov 06, 2008
Bought 176 K USD
TYRRELL JACK
Director
+ 17200
10.25 USD
16 years ago
Nov 06, 2008
Bought 673 USD
TYRRELL JACK
Director
+ 62
10.85 USD
16 years ago
Nov 06, 2008
Bought 540 K USD
TYRRELL JACK
Director
+ 49938
10.82 USD
16 years ago
Nov 05, 2008
Bought 57 K USD
KEYTE DAVID H
Director
+ 5000
11.4 USD
17 years ago
May 07, 2007
Sell 167 K USD
MILES AMY E
Chief Financial Officer
- 7600
21.98 USD
17 years ago
May 07, 2007
Sell 48 K USD
MILES AMY E
Chief Financial Officer
- 2181
21.99 USD
17 years ago
May 07, 2007
Sell 4.4 K USD
MILES AMY E
Chief Financial Officer
- 200
22 USD
17 years ago
May 04, 2007
Sell 411 K USD
Ownby David
Principal Accounting Officer
- 18900
21.77 USD
17 years ago
May 04, 2007
Sell 333 K USD
Ownby David
Principal Accounting Officer
- 15300
21.78 USD
17 years ago
May 04, 2007
Sell 299 K USD
Ownby David
Principal Accounting Officer
- 13700
21.79 USD
17 years ago
May 04, 2007
Sell 207 K USD
Ownby David
Principal Accounting Officer
- 9500
21.8 USD
17 years ago
May 04, 2007
Sell 197 K USD
Ownby David
Principal Accounting Officer
- 9000
21.87 USD
17 years ago
May 04, 2007
Sell 190 K USD
Ownby David
Principal Accounting Officer
- 8700
21.81 USD
17 years ago
May 04, 2007
Sell 190 K USD
Ownby David
Principal Accounting Officer
- 8700
21.84 USD
17 years ago
May 04, 2007
Sell 173 K USD
Ownby David
Principal Accounting Officer
- 7900
21.96 USD
17 years ago
May 04, 2007
Sell 149 K USD
Ownby David
Principal Accounting Officer
- 6800
21.93 USD
17 years ago
May 04, 2007
Sell 140 K USD
Ownby David
Principal Accounting Officer
- 6400
21.89 USD
17 years ago
May 04, 2007
Sell 134 K USD
Ownby David
Principal Accounting Officer
- 6100
21.94 USD
17 years ago
May 04, 2007
Sell 120 K USD
Ownby David
Principal Accounting Officer
- 5500
21.82 USD
17 years ago
May 04, 2007
Sell 119 K USD
Ownby David
Principal Accounting Officer
- 5400
21.98 USD
17 years ago
May 04, 2007
Sell 45.7 K USD
Ownby David
Principal Accounting Officer
- 2100
21.75 USD
17 years ago
May 04, 2007
Sell 28.4 K USD
Ownby David
Principal Accounting Officer
- 1300
21.83 USD
17 years ago
May 04, 2007
Sell 28.5 K USD
Ownby David
Principal Accounting Officer
- 1300
21.9 USD
17 years ago
May 04, 2007
Sell 26.3 K USD
Ownby David
Principal Accounting Officer
- 1200
21.95 USD
17 years ago
May 04, 2007
Sell 19.6 K USD
Ownby David
Principal Accounting Officer
- 900
21.76 USD
17 years ago
May 04, 2007
Sell 17.6 K USD
Ownby David
Principal Accounting Officer
- 800
21.97 USD
17 years ago
May 04, 2007
Sell 8.74 K USD
Ownby David
Principal Accounting Officer
- 400
21.85 USD
17 years ago
May 04, 2007
Sell 2.2 K USD
Ownby David
Principal Accounting Officer
- 100
21.99 USD
17 years ago
May 03, 2007
Sell 148 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 6723
21.99 USD
17 years ago
May 03, 2007
Sell 72.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 3303
22 USD
17 years ago
May 03, 2007
Sell 52.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 2425
21.79 USD
17 years ago
May 03, 2007
Sell 35.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1625
21.78 USD
17 years ago
May 03, 2007
Sell 24.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1141
21.83 USD
17 years ago
May 03, 2007
Sell 22.1 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1009
21.94 USD
17 years ago
May 03, 2007
Sell 20.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 931
21.84 USD
17 years ago
May 03, 2007
Sell 19.1 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 865
22.04 USD
17 years ago
May 03, 2007
Sell 16.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 760
21.91 USD
17 years ago
May 03, 2007
Sell 14.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 655
21.82 USD
17 years ago
May 03, 2007
Sell 13 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 590
21.98 USD
17 years ago
May 03, 2007
Sell 12.6 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 581
21.77 USD
17 years ago
May 03, 2007
Sell 12.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 564
21.81 USD
17 years ago
May 03, 2007
Sell 12.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 563
22.07 USD
17 years ago
May 03, 2007
Sell 11.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 537
22.05 USD
17 years ago
May 03, 2007
Sell 11.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 524
21.75 USD
17 years ago
May 03, 2007
Sell 11.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 524
21.8 USD
17 years ago
May 03, 2007
Sell 10.6 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 485
21.95 USD
17 years ago
May 03, 2007
Sell 7.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 354
22.03 USD
17 years ago
May 03, 2007
Sell 5.74 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 262
21.9 USD
17 years ago
May 03, 2007
Sell 4.05 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 184
22.02 USD
17 years ago
May 03, 2007
Sell 3.18 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 144
22.06 USD
17 years ago
May 02, 2007
Sell 10.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 498
21.84 USD
17 years ago
May 02, 2007
Sell 10.1 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 459
21.9 USD
17 years ago
May 02, 2007
Sell 9.51 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 433
21.97 USD
17 years ago
May 02, 2007
Sell 8.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 393
22.13 USD
17 years ago
May 02, 2007
Sell 8.14 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 367
22.17 USD
17 years ago
May 02, 2007
Sell 7.77 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 354
21.94 USD
17 years ago
May 02, 2007
Sell 7.55 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 345
21.89 USD
17 years ago
May 02, 2007
Sell 7.48 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 341
21.93 USD
17 years ago
May 02, 2007
Sell 6.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 314
21.98 USD
17 years ago
May 02, 2007
Sell 6.99 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 314
22.26 USD
17 years ago
May 02, 2007
Sell 6.12 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 275
22.24 USD
17 years ago
May 02, 2007
Sell 5.83 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 267
21.85 USD
17 years ago
May 02, 2007
Sell 4.62 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 210
22.01 USD
17 years ago
May 02, 2007
Sell 2.33 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 105
22.18 USD
17 years ago
May 02, 2007
Sell 1.75 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 79
22.2 USD
17 years ago
May 02, 2007
Sell 851 USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 39
21.82 USD
17 years ago
May 02, 2007
Sell 867 USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 39
22.23 USD
17 years ago
May 02, 2007
Sell 284 USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 13
21.83 USD
17 years ago
May 02, 2007
Sell 73.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 3355
21.99 USD
17 years ago
May 02, 2007
Sell 64.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 2910
22.27 USD
17 years ago
May 02, 2007
Sell 54.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 2464
22.28 USD
17 years ago
May 02, 2007
Sell 44.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 2032
22 USD
17 years ago
May 02, 2007
Sell 38.1 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1730
22.02 USD
17 years ago
May 02, 2007
Sell 31.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1409
22.22 USD
17 years ago
May 02, 2007
Sell 27.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1245
21.96 USD
17 years ago
May 02, 2007
Sell 25.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1166
22.04 USD
17 years ago
May 02, 2007
Sell 24.6 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1114
22.07 USD
17 years ago
May 02, 2007
Sell 24.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1101
22.06 USD
17 years ago
May 02, 2007
Sell 24 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 1088
22.03 USD
17 years ago
May 02, 2007
Sell 21.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 983
22.1 USD
17 years ago
May 02, 2007
Sell 19.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 904
22.05 USD
17 years ago
May 02, 2007
Sell 18.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 845
22.19 USD
17 years ago
May 02, 2007
Sell 18.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 826
22.14 USD
17 years ago
May 02, 2007
Sell 17.8 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 800
22.29 USD
17 years ago
May 02, 2007
Sell 17.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 786
22.08 USD
17 years ago
May 02, 2007
Sell 16.6 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 761
21.87 USD
17 years ago
May 02, 2007
Sell 16.5 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 747
22.15 USD
17 years ago
May 02, 2007
Sell 16.2 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 734
22.11 USD
17 years ago
May 02, 2007
Sell 15.3 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 694
22.09 USD
17 years ago
May 02, 2007
Sell 15 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 684
21.88 USD
17 years ago
May 02, 2007
Sell 14.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 681
21.91 USD
17 years ago
May 02, 2007
Sell 14.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 668
21.95 USD
17 years ago
May 02, 2007
Sell 13.5 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 616
21.86 USD
17 years ago
May 02, 2007
Sell 13.7 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 616
22.25 USD
17 years ago
May 02, 2007
Sell 13.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 603
22.21 USD
17 years ago
May 02, 2007
Sell 12.4 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 564
21.92 USD
17 years ago
May 02, 2007
Sell 11.9 K USD
BRANDOW PETER B
EVP, General Counsel, Sec.
- 537
22.12 USD
17 years ago
May 03, 2007
Sell 163 K USD
DUNN GREGORY W
EVP and COO
- 7395
21.99 USD
17 years ago
May 03, 2007
Sell 79.9 K USD
DUNN GREGORY W
EVP and COO
- 3632
22 USD
17 years ago
May 03, 2007
Sell 58.1 K USD
DUNN GREGORY W
EVP and COO
- 2667
21.79 USD
17 years ago
May 03, 2007
Sell 38.9 K USD
DUNN GREGORY W
EVP and COO
- 1788
21.78 USD
17 years ago
May 03, 2007
Sell 27.4 K USD
DUNN GREGORY W
EVP and COO
- 1254
21.83 USD
17 years ago
May 03, 2007
Sell 24.4 K USD
DUNN GREGORY W
EVP and COO
- 1110
21.94 USD
17 years ago
May 03, 2007
Sell 22.3 K USD
DUNN GREGORY W
EVP and COO
- 1023
21.84 USD
17 years ago
May 03, 2007
Sell 21 K USD
DUNN GREGORY W
EVP and COO
- 951
22.04 USD
17 years ago
May 03, 2007
Sell 18.3 K USD
DUNN GREGORY W
EVP and COO
- 836
21.91 USD
17 years ago
May 03, 2007
Sell 15.7 K USD
DUNN GREGORY W
EVP and COO
- 721
21.82 USD
17 years ago
May 03, 2007
Sell 14.3 K USD
DUNN GREGORY W
EVP and COO
- 649
21.98 USD
17 years ago
May 03, 2007
Sell 13.9 K USD
DUNN GREGORY W
EVP and COO
- 640
21.77 USD
17 years ago
May 03, 2007
Sell 13.5 K USD
DUNN GREGORY W
EVP and COO
- 620
21.81 USD
17 years ago
May 03, 2007
Sell 13.7 K USD
DUNN GREGORY W
EVP and COO
- 620
22.07 USD
17 years ago
May 03, 2007
Sell 13 K USD
DUNN GREGORY W
EVP and COO
- 591
22.05 USD
7. News
RGC Resources, Inc. Reports 2024 Earnings ROANOKE, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $11,760,896, or $1.16 per share, for the fiscal year ended September 30, 2024, compared to $11,299,282, or $1.14 per share, for the fiscal year ended September 30, 2023. The increase reflected higher levels of earnings from the Company's investment in the Mountain Valley Pipeline (“MVP”) due to more AFUDC in fiscal 2024 prior to the pipeline being placed in service in June 2024. The lower cost of natural gas in 2024 reduced bills to customers and revenues for the Company, despite inflationary costs leading to higher tariffs. Interest expense also increased primarily due to higher interest rates. globenewswire.com - 3 days ago
RGC Resources, Inc. Declares Quarterly Dividend ROANOKE, Va., Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO), at its meeting on September 30, 2024, declared a quarterly dividend of $0.20 per share on the Company's common stock. The dividend will be paid on November 1, 2024 to shareholders of record on October 18, 2024. This is the Company's 322nd consecutive quarterly cash dividend. globenewswire.com - 1 month ago
RGC funding fuels innovation and nurtures young research talents in Hong Kong  Two of the Research Grants Council (RGC)’s key funding schemes - RGC Senior Research Fellow Scheme (SRFS) and RGC Research Fellow Scheme (RFS) - are instrumental in shaping the careers of Hong Kong’s emerging researchers. This article explores the experiences of young research talents mentored by the RGC (Senior) Research Fellows and illustrates how both schemes cultivate future leaders in innovation... scmp.com - 2 months ago
RGC Resources, Inc. Reports Third Quarter Earnings ROANOKE, Va., Aug. 05, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $156,692, or $0.02 per share, for the third quarter ended June 30, 2024, compared to $686,816, or $0.07 per share, for the fiscal quarter ended June 30, 2023. The decline was the result of decreased operating income due to higher personnel and professional costs as well as persistent inflationary pressures across most areas compared to a year ago, along with lower noncash earnings from the Company's investment in the Mountain Valley Pipeline, LLC (“MVP”) as the pipeline transitioned from construction to gas transmission operations. globenewswire.com - 3 months ago
RGC Resources, Inc. Schedules Third Quarter 2024 Earnings Call ROANOKE, Va., July 26, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal third quarter 2024 on Wednesday, August 7, 2024 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at https://www.rgcresources.com/investor-financial-information/ . globenewswire.com - 3 months ago
What Is Going on With Regencell Bioscience (RGC) Stock Today? Little-known drug manufacturer Regencell Bioscience (NASDAQ: RGC ) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it's possible that the exceptionally distinct business profile — specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders — caught the attention of speculators. investorplace.com - 3 months ago
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial HONG KONG–(BUSINESS WIRE)–Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second efficacy trial using standardized Traditional Chinese Medicine (“TCM”) formulae. “Our aim is to save and improve lives by making our standardized TCM formulae widely available to ADHD and ASD patients around the […]... headlinesoftoday.com - 2 years ago
Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second efficacy trial using standardized Traditional Chinese Medicine (“TCM”) formulae. “Our aim is to save and improve lives by making our standardized TCM formulae widely available to ADHD and ASD patients around the world. It is known that there is a significant economic impact and increased parental burden t businesswire.com - 2 years ago
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second efficacy trial using standardized Traditional Chinese Medicine (“TCM”) formulae. “Our aim is to save and improve lives by making our standardized TCM formulae widely available to ADHD and ASD patients around the world. It is known that there is a significant economic impact and increased parental burden to families that care for children with ADHD and ASD. These positive data from the second efficacy trial bring us one step closer to improving the conditions and quality of life of patients and reducing the negative impact that ADHD and ASD have on patients and their families,” said Yat-Gai Au, founder and CEO of Regencell. Second Efficacy Trial The primary objective of the second efficacy trial is to evaluate and assess the effectiveness of Regencell’s standardized TCM formulae in reducing ADHD and ASD symptoms through a holistic approach during the course of a 3-month treatment. The second efficacy trial is a non-blinded efficacy trial. Regencell started its recruitment program in August 2021 through direct invitations to members of a non-governmental organization that serves the ADHD and ASD community. Parents and guardians of children with ADHD and ASD were invited to apply for the program. Patients between the ages of 6 and 12 at the time of the treatment and who were clinically diagnosed with ADHD and/or ASD were eligible to participate in the program. The program required all recruited patients to stop all their existing medications, attend weekly treatment sessions with their parents, and follow the TCM Practitioner’s dietary guidelines, during the 3-month treatment. After a rigorous screening process, Regencell selected 7 children (6 males and 1 female) to participate in the trial. 3 of the patients were diagnosed with ADHD and 4 of them with ASD. All participants resided in Hong Kong. To measure the improvement of the children’s symptoms after taking the TCM Formulae in the trial, Regencell used SKATBT-A3 is a 48-item questionnaire designed and developed by Regencell to evaluate the effectiveness of a treatment in improving ADHD and ASD patients’ symptoms. SKATBT-A3 assesses a patient’s overall physical and neurodevelopmental conditions. SKATBT-A3 includes elements that are conditions of patients usually observed during TCM treatments such as: (i) speech/language/communication; (ii) patients’ sociability; (iii) sensory/cognitive awareness; and (iv) physical health and behavior. For example, SKATBT-A3 examines: The effectiveness of a treatment is demonstrated through the child’s post-treatment tongue control and flexibility, the ability to focus for a longer period of time and less frequent involuntary twitching. Regencell’s formulae aim to improve blood flow to the brain and remove blood clot over time, thereby alleviating symptoms such as inflexibility and twitching. The TCM Practitioner also believes that as the child's heart is strengthened, more blood is delivered to the brain, resulting in an improved ability to focus. All patients orally consumed the standardized TCM formulae twice daily for 3 months. Improvements in patients’ symptoms were assessed weekly during treatment review sessions with the TCM Practitioner and the children’s parents. Second Efficacy Trial Results Change in SKATBT-A3 scores After 3 months of treatment, SKATBT-A3 scores of all patients were lower, indicating fewer problems and improvements in symptoms. Percentage improvement of patients ranged between 14% and 56%, with a mean of 37%. There were noticeable improvements in the patients’ overall health, ADHD symptoms and ASD symptoms. Common improvements include better sleep quality, reduced temper, better bowel movement and healthier complexion. The most notable improvement were demonstrated by two patients who gained the ability to control their tongues naturally without the aid of their own hands after the 3-month treatment. This is noteworthy because limited tongue function affects verbal communications and language abilities. Change in VADRS scores After 3 months of treatment, the VADRS scores of 5 patients were lower, indicating fewer problems and improvements in symptoms, while 1 patient’s score remained the same and 1 patient’s score was higher. Percentage improvements of patients ranged between -21% and 62%, with a mean of 21%. Change in ATEC scores After 3 months of treatment, the ATEC scores of all patients were lower, indicating fewer problems and improvements in symptoms. Percentage improvement of all patients ranged between 4% and 52%, with a mean of 22%. Among the 4 subscales of ATEC, we saw the most significant drop in scores in the health/physical/behavior subscale. Constipation, sleeping problems, poor appetite, anxiety/fearfulness, and irritability are common issues among ADHD and ASD patients. Most of the patients suffered from these symptoms before the treatment but these symptoms improved after the treatment. No adverse side effects None of the patients experienced any adverse side effects after the 3-month treatment. An Unmet Need Millions of children around the world are diagnosed with ADHD and/or ASD and most of the children diagnosed with ADHD had at least one other mental, emotional or behavioral disorder. In addition to going for behavior therapy, medications are also recommended for children who have ADHD and/or ASD. The two main types of medication for ADHD approved by the US Food and Drug Administration (“FDA”) are stimulants and non-stimulants, while the medication for ASD are usually ‘off-labels’ and are not used in a manner specified in the FDA’s approved packaging label or insert. Such medications for ADHD and ASD usually come with side effects such as difficulty sleeping, loss of appetite, headaches, upset stomach and mood swings, amongst others. To address the need for a natural and holistic treatment for such neurocognitive disorders, Regencell is in the midst of conducting further efficacy trials on its standardized TCM formulae to corroborate the effectiveness of the TCM formulae before it is made available to people around the world. Regencell Standardized TCM Formulae Regencell standardized TCM formulae are natural, orally administered liquid TCM formulae for the treatment of ADHD and ASD. In conducting its second efficacy trial, the standardized TCM formulae were administered to children twice daily for a period of 3 months. Regencell standardized TCM formulae were developed by our strategic partner TCM Practitioner based on his Sik-Kee Au TCM Brain Theory® and consists solely of natural ingredients without any synthetic components. The TCM formulae have been used for over 30 years to treat ADHD, ASD and many other neurological illnesses, disorders and diseases and have achieved positive clinical treatment results. The TCM brain theory explains why a healthy brain is essential in restoring the body’s systems to normal. According to the TCM brain theory, the blockage of or reduced blood flow, and damage of the interconnecting central nervous system, endocrine system and blood circulatory system disrupt the production of hormones and transmission of neurotransmitters, such as melatonin, dopamine, and norepinephrine, leading to a defective encoding and decoding of functions, and resulting in deficient or abnormal social behaviors that are the hallmarks of ADHD and ASD. Regencell Bioscience Holdings Limited Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. For more information, please visit www.regencellbioscience.com and www.regencellasia.com. Forward-looking Statements This press release contains “forward‐looking statements” within the meaning of applicable laws, including U.S. federal securities laws. These forward‐looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statements that contain projections of results of operations or of financial condition; statements relating to the research, development, and use of our platform technologies, technologies, products and product candidates; and all statements that address activities, events, or developments that we intend, expect, project, believe, or anticipate will or may occur in the future. The risks and uncertainties of our company include: our ability to obtain regulatory approval and ultimately commercialize our TCM formulae and/or products based on our TCM formulae; the outcome of our research study free from biases of parents or caregivers of patients because we relied on the data provided by them; difficulties enrolling patients in our research studies; any undesirable side effects caused by the TCM formulae candidates which could delay or prevent their regulatory approval or hinder commercialization; whether results of our earlier studies on personalized TCM formulae can be predictive of future research study results; failure of the research and development process; whether any TCM formulae candidates can be developed, manufactured, sold, marketed and distributed; the ability to successfully commercialize any future therapeutics; our ability to enhance our brand recognition; our ability to obtain and protect our intellectual property; and any adverse publicity associated with our TCM formulae candidates, ingredients or network marketing programs. We have based these forward‐looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. We have also relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources and makes no express or implied warranty as to the accuracy or completeness of any such information. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be indicative of results or developments in future periods. For a discussion of these and other risks and uncertainties, see our Annual Report on Form 20-F for the year ended June 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and we undertake no duty to update this information unless required by law. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. businesswire.com - 2 years ago
Sector Rotation And 9 Stocks To Watch During A Recession Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising interest rates and the bond market's inverted yield curve. benzinga.com - 2 years ago
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial   EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patie businesswire.com - 2 years ago
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patients) 90.2 83.8 87.5 Testing negative in 6 days (% of patients) 23.5 43.5 29.7 Recovery period for patients who took RGC-COV19TM within 3 days of symptoms onset (days) 3.7 3.2 3.5 Recovery period for patients who took RGC-COV19TM between 4-5 days of symptoms onset (days) 2.3 3.6 3.4 No longer experienced difficulty breathing and/or persistent chest pain after 1 full dose of RGC-COV19TM (% of patients) 57.1 66.7 66.7 Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 51 individuals enrolled in its additional Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach efficacy trial (the “EARTH-B Trial”) conducted by Regencell Bioscience Asia Limited (“Regencell Asia”) of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). These results are consistent with the earlier analysis announced in February 2022 (the “EARTH-A Trial”), showing RGC-COV19TM is effective in reducing and eliminating COVID-19 symptoms within 6 days, which in turn reduces the risk of hospitalization and death. The results have yet to be peer-reviewed. “Regencell is committed to delivering alternative treatments that are safe and effective through the use of Traditional Chinese Medicine (“TCM”). Rigorous trials have been conducted and results have shown noticeable improvement in COVID-19 symptoms among our trial participants following the administration of RGC-COV19TM. Following the EARTH-B Trial’s results corroborating the effectiveness of RGC-COV19TM, we believe RGC-COV19TM can be a potential treatment that helps rehabilitate COVID-19 patients,” said Ji Yang Lee (Jay), CEO of Regencell Asia. While emerging new COVID-19 variants continue to remain a threat to the public health, Regencell will continue to work in tandem with its R&D units to develop new breakthroughs designed to transform the way COVID-19 is being managed globally and provide safe and effective treatment for everyone. About EARTH The primary objective of EARTH is to evaluate and assess the efficacy of Regencell’s TCM – RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation) in reducing and eliminating COVID-19 symptoms through a holistic approach within a 6-day period. The EARTH B Trial was conducted in Malaysia from 30 January 2022 until 31 March 2022, when Omicron represented 80% of the COVID-19 cases in Malaysia since 10 January 2022, replacing Delta as the dominant COVID-19 strain. The eligibility criteria for enrolment remained the same as the earlier efficacy trial, requiring all patients to have laboratory confirmation of SARS-CoV-2 infection within 3 days prior to treatment and with symptoms onset within 5 days prior to treatment. Based on the above-mentioned criteria, patients who were asymptomatic were rejected and a larger cohort of 51 random individuals qualified and were enrolled for the EARTH-B Trial, as compared to 37 random individuals in EARTH-A Trial. The enrolled patients were between the ages of 11 to 75 and of different races, ethnic backgrounds and socioeconomic backgrounds. All 51 individuals were based in Kuala Lumpur, Malaysia. 48 out of the 51 enrolled patients started taking RGC-COV19TM within 3 days of symptoms onset and the remaining 3 patients started taking RGC-COV19TM between 4 to 5 days of symptoms onset. Regencell Asia set a maximum of 6 days of treatment per patient. Enrolled patients were required to report their COVID-19 symptoms every day according to 3 severity categories (mild, moderate and severe) and the list contained symptoms such as fever, fatigue, cough, sore throat, runny nose, headache, nausea, feeling hot, chills, drowsy, shortness of breath, persistent chest pain or pressure, muscle ache and abdominal discomfort. Patients were also asked to identify any other symptoms they were experiencing. Each patient received 2 days of treatment progressively while a reverse transcription polymerase chain reaction (RT-PCR) test was conducted every 2 days. Whenever a patient’s RT-PCR test result turned negative or patients no longer had any COVID-19 symptoms (save for Sensory Dysfunction or occasional cough) within the 6-day treatment period, the treatment ended. While receiving the TCM treatment, 50 individuals were fully vaccinated and 1 child below 12 years old was not vaccinated. At the end of the treatment, the total number of patients whose symptoms were completely eliminated within the 6-day treatment period, save for Sensory Dysfunction and occasional cough, were recorded to determine the efficacy. About the EARTH-B Trial’s Results Efficacy of complete symptoms elimination within the 6-day treatment period Results from this analysis of 51 trial participants build upon and corroborate previously released data and demonstrate the effectiveness of RGC-COV19TM in eliminating COVID-19 symptoms within 6 days. Of the 51 patients, 48 patients (representing 94.1% of the patients) had all their mild to moderate COVID-19 symptoms eliminated, save for Sensory Dysfunction and occasional cough, within the 6-day treatment period. 17 out of the 51 patients experienced Sensory Dysfunction and among those 17 patients, 11 recovered their sensory functions while the remaining 6 showed improvements at the end of the 6-day treatment period. Out of the 48 patients, the number of days it took for all symptoms to be eliminated, save for Sensory Dysfunction and occasional cough, within the 6-day treatment period, was 1 day = 3 patients, 2 days = 14 patients, 3 days = 9 patients, 4 days = 13 patients, 5 days = 4 patients, and 6 days = 5 patients. Symptoms elimination after 1 full dose of RGC-COV19TM In this analysis, a higher percentage of COVID-19 patients (90.2% compared to the previous efficacy trial of 83.8%), reported the elimination of one or more symptoms after taking 1 full dose of RGC-COV19TM, with the largest number of symptoms eliminated after 1 day of treatment reported by a patient being 8. The average number of days it took from the start of treatment for all 51 patients to eliminate all symptoms, save for Sensory Dysfunction and occasional cough, was approximately 3.6 days. The largest number of different symptoms reported by patients was 16 and the average number of different symptoms reported was approximately 7. Treatment leading to negative RT-PCR 12 patients (representing approximately 23.5%) tested negative RT-PCR within the 6 days treatment (Negative RT-PCR in 2 days = 6 patients, 4 days = 6 patients). Since the start of the treatment, the average days taken for these 12 patients to test negative were 3 days. The minimum and maximum days taken for patients to test negative were 2 and 4 days, respectively. 36 patients had all symptoms eliminated, save for Sensory Dysfunction and occasional cough, within 6 days (average approximately 3.4 days) and therefore was not further tested to obtain a negative RT-PCR result. Taking the treatment within 3 days from symptoms onset vs within 4 to 5 days from symptoms onset The recent analysis showed that 48 out of the 51 patients started taking RGC-COV19TM within 3 days from symptoms onset and they took an average of approximately 3.7 days for the elimination of all symptoms, save for Sensory Dysfunction and occasional cough, whereby the maximum number of different symptoms reported by any one individual was 16 and the average number of different symptoms reported was 8. The remaining 3 patients who started taking RGC-COV19TM between 4 to 5 days from symptoms onset took an average of approximately 2.3 days for the elimination of all symptoms, save for Sensory Dysfunction and occasional cough, whereby the maximum number of different symptoms reported by any one individual was 8 and the average number of symptoms reported was 5. Vaccination status 50 individuals were fully vaccinated and 1 child below 12 years old was not vaccinated. All 12 patients who tested negative RT-PCR in 4 days were fully vaccinated prior to taking the RGC-COV19TM treatment. All patients who were vaccinated received vaccine from either Pfizer-BioNTech, AstraZeneca or Sinovac-CoronaVac, which are the top 3 vaccines distributed in Malaysia. High-risk patients Out of the 51 patients, 15 patients experienced a combination of dyspnea (difficulty breathing) and/or persistent chest pain. 10 of these 15 patients no longer experienced difficulty breathing and/or persistent chest pain after 1 full dose of RGC-COV19TM. No adverse side effects Based on the patients’ self-reported data, there were no worsening of symptoms during and after consuming RGC-COV19TM and none of the patients experienced any unknown adverse side effects. No treatment emergent adverse events Among the patients with chronic conditions such as chronic migraine, eczema, asthma, thyroid disease, high blood pressure and high cholesterol, there were no treatment emergent adverse events and no discontinuation of RGC-COV19TM due to adverse results. Death/Hospitalization At the end of the EARTH-B Trial, none of the patients was hospitalized and there was no death. The efficacy of RGC-COV19TM was not affected by timing of symptom onset or underlying risk factors. Results were consistent across all ages, gender, races and ethnicity demographic among the enrolled patients. More about EARTH There are hundreds of millions of individuals who have been diagnosed with COVID-19 around the world, and some experience post-COVID symptoms such as extreme tiredness (fatigue), shortness of breath, problems with memory and concentration (brain fog), heart palpitations, dizziness, chest pain or tightness, joint pain which are now being classified as long-COVID symptoms. As long-COVID symptoms have substantial effects on individuals’ quality of life and work capability, Regencell Asia is in the midst of conducting its studies for long-COVID patients using a natural and holistic formula - RGC-COV19TM (RGCA-LCV01). About RGC-COV19TM RGC-COV19TM (RGCA-CV01) is an investigational, natural, orally administered liquid formula which aims to reduce and eliminate COVID-19 symptoms. RGC-COV19TM is a natural formula designed by the TCM Practitioner according to the TCM Practitioner’s brain theory known as “Sik-Kee Au TCM Brain Theory®” and can be taken safely for two to three weeks. In conducting EARTH, the treatment was limited to 6 days in order to evaluate its efficacy in reducing and eliminating COVID-19 symptoms. The “TCM Practitioner” refers to our strategic TCM research partner, Sik-Kee Au, father of our founder and Chief Executive Officer. According to the brain theory, brain functions depend on the oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart’s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response. RGC-COV19TM is designed to strengthen the heart’s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions. Regardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage by setting off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which in turn suppress brain functions. RGC-COV19TM is formulated to generate more responsive cognitive functions which in turn stimulate the body’s own healing mechanism. Regencell began its investigational approach towards COVID-19 treatment when a friend of Regencell contracted COVID-19 in March 2020. To treat his friend, the TCM Practitioner used his proprietary TCM formula which he has been using over the past 30 years to treat various cold and flu patients, including during the 2003 SARS outbreak. The TCM Practitioner subsequently treated 9 voluntary COVID-19 patients in the United States using the proprietary TCM formula. Study results showed that the treatment was effective. As Regencell has a mission to save lives, improve patients’ well-being and address unmet needs in the market, Regencell aims to make its natural and holistic treatment available to everyone in need. From March 2020 to August 2021, Regencell set up protocols and procedures to conduct the EARTH efficacy trial in Malaysia and the United States. RGC-COV19TM is designed to reduce COVID-19 symptoms such as fever, fatigue, cough, sore throat, runny nose, headache, nausea, chills, drowsiness, shortness of breath, persistent chest pain and muscle ache as the medicine works to (i) reduce and clear the mucus and phlegm from the upper respiratory system; (ii) dispel exterior viral pathogen via heavy sweats, urine and excrement; (iii) clear endogenous and liver heat; (iv) detox the liver; and (v) improve body circulation. By applying the TCM Practitioner’s “Sik-Kee Au TCM Brain Theory®”, RGC-COV19TM is also designed to remove blood clots from the brain and restore the patient's brain functions. RGC-COV19TM (RGCA-CV01) is administered at 1 dose of RGCA-CV01-1Na (approximately 230ml) and 1 dose of RGCA-CV01-2Da (approximately 230ml) each time, with 1 dose of RGCA-CV01-1Na to be taken starting from the night of the first day of treatment and 1 dose of RGCA-CV01-2Da to be taken after lunch the next day, until symptoms are eliminated. About Regencell Bioscience Holdings Limited and Regencell Bioscience Asia Limited: Breakthrough in TCM formulae designed to save and improve lives For more than 30 years, the TCM Practitioner whom Regencell partners with has treated patients with neurological disorders and infectious diseases. The TCM Practitioner’s TCM formulae candidates are derived from a TCM base formula and an adjustable formula which is developed based on his TCM brain theory, known as the “Sik-Kee Au TCM Brain Theory®”. Both Regencell and the TCM Practitioner are committed in giving back to the society and demonstrates its CARE through Caring for patients, Accountability by maintaining a high standard of quality and integrity, Respect by valuing partnerships, teamwork and harmony and the Enthusiasm to improve the life of the underprivileged. Since its listing, Regencell through a joint venture with Honor Epic Enterprises Limited, formed Regencell Bioscience Asia Limited to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand, as Regencell aspires to be the global market leader for the provision of natural and holistic treatment for neurological disorders and infectious diseases. For more information, visit www.regencellbioscience.com and www.regencellasia.com. Forward-looking Statements This press release contains “forward‐looking statements” within the meaning of applicable laws, including U.S. federal securities laws. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statements that contain projections of results of operations or of financial condition; statements relating to the research, development, and use of our platform technologies, technologies, products and product candidates, including with respect to our Investigational Liquid-Formula RGC-COV19TM; and all statements that address activities, events, or developments that we intend, expect, project, believe, or anticipate will or may occur in the future. The risks and uncertainties of our company include: our ability to obtain regulatory approval and ultimately commercialize our TCM formulae and/or products based on our TCM formulae; the outcome of our research study free from biases of parents or caregivers of patients because we relied on the data provided by them; difficulties enrolling patients in our research studies; any undesirable side effects caused by the TCM formulae candidates which could delay or prevent their regulatory approval or hinder commercialization; whether results of our earlier studies on personalized TCM formulae can be predictive of future research study results; failure of the research and development process; whether any TCM formulae candidates can be developed, manufactured, sold, marketed and distributed; the ability to successfully commercialize any future therapeutics; our ability to enhance our brand recognition; our ability to obtain and protect our intellectual property; and any adverse publicity associated with our TCM formulae candidates, ingredients or network marketing programs. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. We have also relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources and makes no express or implied warranty as to the accuracy or completeness of any such information. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be indicative of results or developments in future periods. For a discussion of these and other risks and uncertainties, see our Annual Report on Form 20-F for the year ended June 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and we undertake no duty to update this information unless required by law. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. businesswire.com - 2 years ago
8. Profile Summary

Regencell Bioscience Holdings Limited RGC

image
COUNTRY HK
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 79.8 M
Dividend Yield 0.00%
Description Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Contact First Commercial Building, Causeway Bay, KY1-1107 https://www.regencellbioscience.com
IPO Date July 16, 2021
Employees 12
Officers Mr. Yat-Gai Au Founder, Chairman & Chief Executive Officer Mr. Yat-Pui Au Chief Business Officer Ms. Antonia Assang Senior Vice President of Project Management Mr. Wai Hong Chung Chief Operating Officer, Chief Strategy Officer & Director Ms. Michelle Chan Financial Controller & Principal Financial Officer